Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?

Thromboembolic events contribute to morbidity and mortality in coronavirus disease 2019 (COVID-19). As a result, thromboprophylaxis using low-molecular-weight heparin (LMWH) is universally recommended for hospitalized patients based on multiple guidelines. However, ethnic differences with respect to...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology Vol. 113; no. 3; pp. 330 - 336
Main Authors: Iba, Toshiaki, Connors, Jean Marie, Spyropoulos, Alex C., Wada, Hideo, Levy, Jerrold H.
Format: Journal Article
Language:English
Published: Singapore Springer Singapore 01.03.2021
Springer Nature B.V
Subjects:
Anticoagulants
Anticoagulants - administration & dosage
Anticoagulants - adverse effects
Biological Variation, Population
Bleeding
Coronaviruses
COVID-19
COVID-19 - complications
COVID-19 - epidemiology
COVID-19 - virology
Cultural differences
Disease Management
Disease Susceptibility
Ethnicity
Hematology
Heparin
Humans
Medicine
Medicine & Public Health
Minority & ethnic groups
Morbidity
Mortality
Oncology
Post-Exposure Prophylaxis
Prognosis
Review
Review Article
SARS-CoV-2
Thromboembolism
Thromboembolism - diagnosis
Thromboembolism - epidemiology
Thromboembolism - etiology
Thromboembolism - prevention & control
Thrombosis
Venous Thromboembolism - etiology
Venous Thromboembolism - prevention & control
Viral diseases
COVID-19
Ethnic difference
Deep vein thrombus
Thromboprophylaxis
Thromboembolism
ISSN:0925-5710, 1865-3774, 1865-3774
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thromboembolic events contribute to morbidity and mortality in coronavirus disease 2019 (COVID-19). As a result, thromboprophylaxis using low-molecular-weight heparin (LMWH) is universally recommended for hospitalized patients based on multiple guidelines. However, ethnic differences with respect to thrombogenicity have been reported and the incidence of thromboembolic events is considered to be lower in the Asian population. Despite the importance of thromboprophylaxis, bleeding is also a side effect that should be considered. We examine the data relating to potential ethnic differences in thrombosis and bleeding in COVID-19. Although sufficient data is not yet available, current evidence does not oppose routine anticoagulant use and thromboprophylaxis using a standard dose of LMWH for admitted patients regardless of ethnicity based on our review.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0925-5710
1865-3774
1865-3774
DOI:10.1007/s12185-021-03078-x